SAM
IONS icon

Shell Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Shell Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,265
Closed -$498K – 1367
2022
Q3 		$498K Sell
11,265
-2,951
-21% -$124K 0.02% 568
2022
Q2 		$526K Buy
14,216
+3,194
+29% +$120K 0.02% 689
2022
Q1 		$408K Sell
11,022
-1,629
-13% -$53.3K 0.01% 908
2021
Q4 		$385K Buy
12,651
+48
+0.4% +$1.51K 0.01% 1011
2021
Q3 		$423K Sell
12,603
-566
-4% -$21.3K 0.01% 939
2021
Q2 		$525K Sell
13,169
-32,964
-71% -$1.29M 0.01% 888
2021
Q1 		$2.07M Buy
46,133
+33,597
+268% +$1.87M 0.04% 346
2020
Q4 		$709K Buy
12,536
+3,217
+35% +$160K 0.01% 627
2020
Q3 		$442K Hold
9,319
– – 0.01% 734
2020
Q2 		$549K Sell
9,319
-4,476
-32% -$249K 0.01% 619
2020
Q1 		$652K Sell
13,795
-127
-0.9% -$7.08K 0.02% 560
2019
Q4 		$841K Sell
13,922
-2,924
-17% -$174K 0.02% 622
2019
Q3 		$1.01M Sell
16,846
-74
-0.4% -$4.82K 0.02% 529
2019
Q2 		$1.09M Buy
16,920
+2,808
+20% +$198K 0.02% 518
2019
Q1 		$1.15M Hold
14,112
– – 0.03% 504
2018
Q4 		$763K Sell
14,112
-1,200
-8% -$61.2K 0.02% 634
2018
Q3 		$790K Hold
15,312
– – 0.02% 798
2018
Q2 		$638K Sell
15,312
-819
-5% -$36.3K 0.01% 866
2018
Q1 		$711K Buy
+16,131
New +$820K 0.01% 805
2016
Q4 		– Sell
-2,296
Closed -$84K – 1076
2016
Q3 		$84K Sell
2,296
-3,219
-58% -$101K ﹤0.01% 1007
2016
Q2 		$128K Sell
5,515
-618
-10% -$19.9K ﹤0.01% 857
2016
Q1 		$248K Hold
6,133
– – 0.01% 806
2015
Q4 		$380K Buy
+6,133
New +$331K 0.01% 746
2015
Q3 		– Sell
-11,223
Closed -$646K – 871
2015
Q2 		$646K Buy
11,223
+334
+3% +$21.2K 0.01% 708
2015
Q1 		$693K Buy
+10,889
New +$739K 0.01% 724

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Shell Asset Management's IONS Position: Q4 2022 in Review

Shell Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 11,265 shares — an estimated $498K sold.

Shell Asset Management first reported a position in IONS in Q1 2015 and held it in 25 quarters. The position peaked at $2.07M in Q1 2021. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

  • Shell Asset Management reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Shell Asset Management sold 11,265 Ionis Pharmaceuticals shares in Q4 2022, an estimated $498K.
  • Shell Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 25 quarters.
  • Shell Asset Management's Ionis Pharmaceuticals position peaked at $2.07M in Q1 2021.
  • 338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on Shell Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.